Of all the problems in Lyme disease medicine, diagnostics may be the most foundational. A test that misses cases doesn't just delay treatment — it prevents people from receiving the care they need, allows the disease to progress, and fuels the kind of dismissal that can permanently damage a patient's trust in the healthcare system.
The Current Standard and Its Limitations
The CDC-recommended two-tier testing protocol — an ELISA or enzyme immunoassay followed by Western blot — detects antibodies produced by the immune system in response to Borrelia burgdorferi infection. While reliable for later-stage disease, this approach has critical weaknesses:
- Early-stage insensitivity: In the first 2–3 weeks of infection, sensitivity is only 30–50% because the immune response has not yet produced detectable antibody levels.
- Inability to distinguish active from past infection: Antibodies can persist for years after successful treatment, meaning a positive test doesn't distinguish current from historical infection.
- Limited utility for treatment monitoring: Test results do not reliably track treatment response or confirm cure.
The Research Frontier
Project Lyme has funded research in several promising diagnostic directions:
Novel Biomarker Detection for Early Lyme Disease
This study is investigating a panel of host-response biomarkers — metabolites and cytokines — that change rapidly during early Lyme infection, potentially enabling accurate diagnosis within days of exposure.
Direct Pathogen Detection Using Next-Generation Sequencing
Moving beyond antibody detection, this project tests whether sensitive nucleic acid sequencing can identify Borrelia DNA in blood samples at concentrations too low for conventional PCR — enabling detection before the immune response begins.
Why This Matters for Patients
Every year that the diagnostic gap persists, hundreds of thousands of Americans receive delayed diagnoses. Better tests mean faster treatment, less disease progression, and fewer people spending years seeking answers that should have come much sooner.